Overview: The pharmaceutical industry's daily monitor, with emphasis on post-marketing topics, market development, and corporate earnings.

Newsletter Subscribers: 60,000+

Publishing Schedule: daily

Audience: Senior pharmaceutical industry executives, project managers, brand managers, and other insiders at pharmaceuticals.

Reader Demographics

Company Type
Pharmaceutical - 33%
Biotechnology - 11%
Academia / Government Research / Other Research - 7%
Consulting - 18%
Marketing / Media - 5%
Finance / PE / VC - 5%
Other - 13%

Job Function
Corporate Management (CEO, CFO, COO, CIO, SVP, VP) - 26%
R&D and Lab Management - 23%
Sales & Marketing - 15%
Product/Brand Management - 6%
Licensing / Business Development - 4%
Finance - 5%
Manufacturing / Production - 3%
Regulatory / Labeling / Safety - 3%
IT - 1%
Other - 15%

Region
North America - 80%
Europe - 14%
Asia-Pacific - 4%
Central & South America - 1%

69% of FiercePharma readers have an advanced degree.

64% of FiercePharma readers supervise others.

64% of FiercePharma readers make purchasing decisions.


Advertising Contact:

Ryan Willumson
(202) 824-5089
ryan@fiercemarkets.com

Enter your contact information to see current rates and packages.

Name*: Company*: Email*:

FiercePharma Audience - Top 25 Ranked by Readership

  • Pfizer
  • GSK
  • Merck
  • Amgen
  • J&J
  • Abbott
  • Bristol Myers Squibb
  • Genentech
  • Hoffman LaRoche
  • Eli Lilly
  • Schering-Plough
  • Aventis
  • AstraZeneca
  • Boehringer Ingelheim
  • Bayer
  • Sanofi
  • Baxter
  • Allergan
  • Novartis
  • MedImmune
  • Gilead
  • Takeda
  • Genzyme
  • Cephalon
  • Novo Nordisk
  • Vertex
  • Procter & Gamble
  • Elan
  • Covance